It’s been relatively smooth sailing for AstraZeneca and Merck’s Lynparza as it has gained indications in ovarian, breast, pancreatic and prostate cancer. But on Thursday, the companies reported a snag ...
Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its investigational, once-daily, oral, two-drug, single-tablet regimen of ...
Merck MRK announced that the FDA had accepted the biologics license application (“BLA”) seeking approval for sotatercept, its novel investigational activin signaling inhibitor, as a potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results